Wardwizard Healthcare approved a preferential issue of up to 1,25,00,000 fully convertible warrants worth ₹12.5 crore during its board meeting on August 31, 2026. The company also increased its authorized share capital from ₹7.5 crore to ₹25 crore.

The board sanctioned the issuance at ₹10 per warrant, determined in accordance with Chapter V of SEBI (ICDR) Regulations, 2018. Each warrant is convertible into one equity share of ₹10 face value within 18 months of allotment. Unconverted warrants will lapse, and the amount paid will be forfeited. Proceeds will fund growth initiatives, working capital, and investments in group entities such as Wardwizard Medicare Private Limited.

Capital Structure Changes

The authorized capital increase allows the company to issue up to 2.5 crore equity shares of ₹10 face value each, replacing the previous limit of 75 lakh shares. The new shares rank pari-passu with existing equity.

Promoter and Investor Participation

Promoters Yatin Sanjay Gupte and Sheetal Mandar Bhalerao are among the proposed allottees. Gupte holds 37.04% of pre-issue shares (90,750 shares) and is allotted 52,00,000 warrants. Post-conversion, his stake would rise to 41.51%. Bhalerao holds 14.19% (34,760 shares) and receives 18,00,000 warrants, bringing his post-conversion holding to 14.40%.

Non-promoter allottees include Ram Chander Sharma, Nitu Sharma, Ram Chander Sharma HUF, Shyam Sunder Sharma, Hemlata Sharma, Shyam Sunder Sharma HUF, Aakanksha Kabra, Ilyashbhai Dhobi, Sanjay Kumar Sharma, Pooja Chotia, Havish Suppliers LLP, Kailash Dhanuka HUF, Ruchika Dhanuka, Arpit Kabra, P. B. Films Limited, and Kyan Investment & Trading Company Private Limited. No single non-promoter entity exceeds a 4.94% post-conversion stake.

Board Appointments

Ms. Sathi Kundu was appointed as an additional independent director for a five-year term effective August 31, 2026. She brings over 15 years of legal experience. Her appointment requires shareholder approval at the upcoming annual general meeting.

Mr. Yuvraj Priyadarshi was appointed as whole-time director effective September 30, 2026. He previously served as CEO since November 14, 2025. His five-year term is subject to shareholder ratification.

Annual General Meeting

The 42nd AGM is scheduled for September 30, 2026, via video conferencing. Remote e-voting will run from September 27 to September 29, 2026. The register of members remains closed from September 23 to September 30, 2026.

Wardwizard Healthcare has scheduled a meeting of its Board of Directors for Monday, August 31, 2026. The primary agenda includes considering proposals for raising further capital and increasing the authorized share capital.

The company intends to discuss the creation, offer, issue, and allotment of equity shares and equity-linked instruments. This may include convertible preference shares, non-convertible debt instruments with warrants, fully or partly convertible debentures, Global Depository Receipts, American Depository Receipts, and Foreign Currency Convertible Bonds.

Capital Raising Modes

The proposed capital raising can occur through public or private offerings, qualified institutional placements, preferential allotments, or other permissible modes under applicable laws. Any such issuance will require shareholder approval at an ensuing General Meeting and relevant regulatory approvals.

In addition to the capital raise, the Board will consider an increase in the authorized share capital and consequential alterations to Clause V of the Memorandum of Association.

Trading Window Closure

In compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the company's securities is closed for all Designated and Connected persons and their immediate relatives. This closure began on August 24, 2026, and will remain in effect until 48 hours after the announcement of the Board Meeting outcome.

The intimation was issued under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Rajbala Kiroriwal, Company Secretary and Compliance Officer, signed the communication.